Oxford Biomedica Appoints Namrata P Patel as Non-Executive Director

13 April 2022

Oxford, UK – 13 April 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, announces the appointment of Ms. Namrata P Patel to the Board as an Independent Non-Executive Director with immediate effect.

Ms. Patel has extensive international experience in manufacturing and end to end Supply Chain with experience in the commercialised regulated industry. She is currently SVP, Product Supply, within the Global Beauty Sector at Procter & Gamble (NYSE: PG), a US-listed, multi-national consumer goods business, having joined the company 25 years ago. Ms. Patel has held senior positions across several major global markets, and plays a key role in delivering on Procter & Gamble’s 2040 Sustainability Ambition Goals for its Beauty Business portfolio.

Over the course of her career, Ms. Patel has worked at a number of major multi-national corporations, holding senior positions at Gillette, WH Smith and Coca-Cola, with a strong focus on international supply chain management. She holds a Masters in Logistics and Management from the Cranfield School of Management, and a BA in Public Administration & Marketing from the University of South Wales, Mid Glamorgan.

Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: “Namrata is a high calibre and timely appointment for Oxford Biomedica as we advance our manufacturing and CMC capabilities, whilst expanding our global presence. We warmly welcome her to the Board and look forward to utilising her international manufacturing and supply chain expertise, as well as her experience in sustainability as we deliver on our aim of becoming a global fully integrated viral vector leader.”

Ms. Namrata Patel said: “Oxford Biomedica is at an exciting time in its development as it broadens its scope into AAV and significantly expands its manufacturing capacity to meet the growing global demand for its viral vector capabilities. I look forward to working closely with the rest of the Board and the management team as the Company continues to progress as a global leader in the gene and cell therapy space.”

Relevant disclosures
There are no disclosures required to be made in accordance with LR 9.6.13R.



Oxford Biomedica plc:
T: +44 (0)1865 783 000 / E: ir@oxb.com
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, Head of Investor Relations

Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Neal 

About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group. In January 2022, Oxford Biomedica announced that it was broadening its leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as a 20% owner. To date, Oxford Biomedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Boehringer Ingelheim, Beam Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com.